首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

1869572

mRNA合成與生產市場：產業趨勢及全球預測（至2035年）－依產品、企業規模、合成與生產活動、適應症類型、治療領域、應用領域及地區劃分

mRNA Synthesis and Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Product, Scale of Operation, Synthesis and Manufacturing Activity, Indication Type, Therapeutic Area, Application Area and Geographical Regions

出版日期: 2025年10月24日 | 出版商:

Roots Analysis | 英文 341 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

mRNA合成與生產市場：概論

根據Roots的分析，mRNA合成與生產市場預計將以20%的複合年增長率成長，從2028年的11.5億美元成長到2035年的13.5億美元。

mRNA合成與生產市場

市場規模和機會分析基於以下參數進行區隔：

產品類型

活性藥物成分
成品劑型

企業規模

臨床前和臨床規模
商業規模

合成與生產活性

合約生產
內部生產

適應症類型

COVID 相關適應症
非 COVID 適應症

治療領域

傳染病
腫瘤學
其他

應用

mRNA 疫苗
mRNA 療法

地區

北美
歐洲
亞太地區
拉丁美洲
中東和北非

mRNA 合成與生產市場：成長與趨勢

核糖核酸 (RNA) 是存在於所有生物細胞中的分子。它將遺傳訊息轉化為各種蛋白質，並執行各種細胞功能。重要的是，RNA 以多種形式存在，包括信使 RNA (mRNA)、轉移 RNA (tRNA) 和核醣體 RNA (rRNA)。其中，mRNA 已成為現代醫療保健產業中至關重要的治療方法。

mRNA 是一種單股 RNA 分子，它傳遞 DNA 中包含的遺傳訊息以進行蛋白質合成。 mRNA 上的遺傳訊息翻譯成胺基酸，然後胺基酸被加工成功能性產物（蛋白質）。尤其是在 COVID-19 大流行期間，mRNA 疫苗和治療藥物的生產已成為治療 COVID-19 感染的一種有前景的下一代藥物。此外，mRNA 療法也正在被評估用於治療各種腫瘤、傳染病和遺傳性疾病。這種多功能性和可擴展性促成了mRNA療法的廣泛應用，使其成為個人化mRNA療法生產和疫苗開發的基礎。此外，較低的插入突變風險有望提高患者的安全性。

這一成功顯著增加了對mRNA合成和生產的需求，mRNA療法和疫苗開發者正在積極尋求替代方案以滿足當前的需求。在這方面，外包已成為mRNA療法和疫苗開發公司的有利可圖的選擇，為mRNA療法和疫苗開發提供了一種有效且可擴展的解決方案。考慮到mRNA合成和生產領域的當前趨勢和預期機遇，預計該行業在不久的將來將實現個位數的市場成長。

mRNA合成與生產市場：主要發現

本報告深入分析了mRNA合成和生產市場的現狀，並指出了該行業的潛在成長機會。主要發現包括：

在當前市場格局中，全球約有 55 家供應商聲稱提供客製化 mRNA 合成服務，其中 60% 的總部位於北美。

mRNA Synthesis and Manufacturing Market-IMG1

2. 大多數 mRNA 客製化合成服務提供者（約 95%）提供 mRNA 的 5' 端修飾。這主要是為了提高 mRNA 的穩定性、翻譯效率並降低免疫原性風險。

3. 各利益相關者正在積極提升現有能力，以增強其產品組合，並在 mRNA 定制合成領域獲得相對於其他公司的競爭優勢。

4. 隨著對mRNA疫苗的需求不斷增長，以及mRNA合成和生產技術的進步，目前約有45家公司積極提供mRNA合約生產服務。

5. 約60%的公司提供mRNA原料藥和製劑的合約生產服務，約90%的公司提供臨床規模的mRNA合約生產服務。

6. mRNA合約生產服務提供者正積極拓展和豐富其mRNA生產能力，以增強其服務組合併建立具有競爭力的市場基礎。

7. 目前市面上約有115種mRNA合成試劑盒，適用於包括分子生物學、蛋白質生產和疫苗研發在內的廣泛應用。

8. mRNA合成試劑盒包含多種組件，以滿足客戶的特定需求。特別是T7聚合酶，已成為最受歡迎的酵素類型，超過95%的mRNA合成試劑盒都包含此酵素。

9. 目前市面上約有115種mRNA合成試劑盒。這些試劑盒適用於多種應用，包括分子生物學、蛋白質生產和疫苗研發。

10. mRNA合成試劑盒包含多種組分，以滿足客戶的特定需求。特別是T7聚合酶，已成為最受歡迎的酵素類型，超過95%的mRNA合成試劑盒都包含此酵素。

11. 近年來，各利害關係人之間建立了多種合作關係，也反映了市場對該領域日益增長的興趣。事實上，約50%的交易是在過去三年內達成的。

12.全球眾多以mRNA為基礎的治療藥物和疫苗研發企業預計將與mRNA合成和生產服務提供者建立策略合作夥伴關係，以進一步拓展其藥物產品組合。

13. 賽諾菲在該領域佔主導地位，引領著大多數大型製藥公司在該領域的活動（約佔30%），其大部分舉措（50%）都是與該領域各利益相關方建立的合作夥伴關係和合作項目。

14. 北美目前佔mRNA合成和生產市場的大部分佔有率。這很可能是由於該地區擁有先進的醫療基礎設施，使企業能夠進行廣泛的研究。

15. 由於mRNA療法和疫苗在治療傳染病方面具有顯著療效，預計今年傳染病區隔市場將佔整體市場的大部分佔有率。

mRNA Synthesis and Manufacturing Market-IMG2

16. 預計北美將佔 mRNA 合成與製造市場的大部分佔有率，且這一趨勢預計將保持不變。

17. 受美國主要公司基於 mRNA 的疫苗和療法快速成功的推動，mRNA 合成與製造市場預計將以 6.5% 的複合年增長率增長。

mRNA合成與生產市場：主要區隔市場

活性藥物成分佔mRNA合成與生產市場最大佔有率

據我們估計，今年活性藥物成分區隔市場預計將佔mRNA合成與生產市場的大部分佔有率（超過60%）。這是因為活性藥物成分是任何治療藥物/疫苗的基本組成部分，影響產品的整體療效和安全性。

商業化規模佔mRNA合成與生產市場最大佔有率

今年，由於眾多以mRNA為基礎的治療藥物和疫苗的商業化，商業化規模區隔市場佔最大佔有率（超過85%）。此外，臨床前和臨床規模市場預計在預測期內將保持溫和成長。該領域的大量研發投入正在推動臨床前和臨床領域的成長，進而促進基於mRNA的產品開發。此外，各公司正致力於擴大其mRNA生產設施，以提升不同規模的生產能力。

預計合約生產將主導mRNA合成和生產市場。

今年，合約生產區隔市場佔最大的市場佔有率（約60%）。這一主導地位主要歸因於mRNA生產的複雜性，它需要專業技術，並且通常依賴第三方服務提供者。此外，預計在預測期內，內部生產區隔市場的佔有率將顯著增長，複合年增長率（CAGR）為7.5%。

預計在預測期內，非COVID適應症將以顯著的複合年增長率成長。

今年，COVID-19相關適應症區隔市場佔最大的市場佔有率（95%）。這是因為基於mRNA的產品可以引導細胞產生特定的病原體蛋白，從而在不接觸實際病原體的情況下觸發強效且標靶的免疫反應。此外，非新冠肺炎適應症的市佔率預計將顯著成長，在預測期內複合年增長率將達到37.5%。

聚焦傳染病mRNA療法

今年，傳染病區隔市場佔了最大的市場佔有率（約95%）。這主要歸功於mRNA療法和疫苗在對抗新冠肺炎疫情方面的巨大成功。此外，由於癌症發生率不斷上升以及開發新型治療策略以有效治療腫瘤疾病的需求，腫瘤領域預計將迎來顯著的市場成長。

mRNA疫苗將佔mRNA合成和生產市場的最大佔有率。

根據mRNA合成和生產市場預測，mRNA疫苗區隔市場預計將在今年推動市場成長，這主要得益於其已證實的臨床成功、廣泛的預防應用潛力以及靈活的特性。此外，mRNA療法的佔有率預計將顯著增長，在預測期內複合年增長率將達到61.1%。這主要歸功於mRNA療法在腫瘤、遺傳性疾病、自體免疫疾病和心血管疾病等領域的治療應用快速擴展，為mRNA療法創造了強勁的臨床發展動力。

未來幾年，北美將引領mRNA合成與生產領域。

預計北美將佔大部分市場佔有率（超過40%）。此外，預計北美市場在預測期內將以6.6%的複合年增長率成長。這主要歸功於北美先進的醫療基礎設施、業內多家企業所進行的廣泛研究以及其多元化的市場環境。這有助於開發用於各種治療適應症的新型 mRNA 療法。

mRNA 合成與生產市場的主要參與者

Aldevron
APExBIO
Aurigene Pharmaceutical Services
BioCell
Biomay
BioNTech
Biorbyt
CELLSCRIPT
Creative Biogene
Curia
Eurogentec
GenScript
eJena Bioscience
Lonza
Merck
Porton Advanced
Revolution Biotechnology
Samsung Biologics
ST Pharm
Thermo Fisher Scientific
TriLink BioTechnologies
Vernal Biosciences
WuXi生物製劑
YXgene

Ribonucleic acid (RNA) is a molecule found in all living cells that translates genetic information into different proteins to carry out various cellular functions. Importantly, RNA can exist in various forms, such as messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). Amongst these, mRNA has become a crucial therapeutic approach in modern healthcare industry.

mRNA is a single-stranded RNA molecule that carries the genetic information found in DNA to synthesize proteins. The genetic information found on mRNA is translated into amino acids, which are then processed into a functional product (proteins). Significantly, following the COVID-19 pandemic, the production of mRNA vaccines and therapeutics has attracted notable focus as they have developed into a next-generation class of drugs for treating the COVID-19 infection. Additionally, mRNA therapies are being assessed for the management of different oncological, infectious, and genetic conditions. This versatility and scalability of mRNA therapeutics have further contributed to their adoption, positioning them as a cornerstone of personalized mRNA medicine production and vaccine development. Moreover, these therapies are expected to possess enhanced safety profiles for patients due to the low risk of insertional mutagenesis.

Due to this success, the need for mRNA synthesis and production has risen significantly, leading mRNA therapeutic /vaccine developers to actively investigate alternatives to meet the current demand. In this regard, outsourcing became a profitable choice for companies involved in mRNA therapeutic / vaccine development, providing effective and scalable solutions for mRNA therapeutics and vaccine development. Given the current trends and anticipated opportunities in the mRNA synthesis and manufacturing sector, we anticipate that this field is poised for single-digit market growth in the near future.

mRNA SYNTHESIS AND MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the mRNA synthesis and manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

1. The current market landscape features the presence of close to 55 providers that claim to offer customized services for mRNA synthesis across the world; 60% of these are headquartered in North America.

2. Majority (~95%) of the mRNA custom synthesis service providers offer 5' modifications of mRNA, primarily because it enhances mRNA stability, translation efficiency and reduces chances of immunogenicity.

3. Stakeholders are actively upgrading their existing capabilities in order to enhance their respective portfolios and gain a competitive edge over other players active in the mRNA custom synthesis domain.

4. Owing to the rising demand for mRNA vaccines coupled with advancements in mRNA synthesis and manufacturing technologies, ~45 companies are actively offering mRNA contract manufacturing services.

5. Around 60% of the companies are offering mRNA contract manufacturing services for both drug substances and drug products; ~90% players offer mRNA contract manufacturing services at clinical scale.

6. mRNA contract manufacturing service providers are proactively enhancing and diversifying their mRNA manufacturing capabilities to strengthen their service portfolios and establish a competitive market foothold.

7. Presently, close to 115 kits are available in the market for mRNA synthesis; these kits are designed to cater to a wide range of applications, including molecular biology, protein production and vaccine development.

8. mRNA synthesis kits comprise of a variety of components, catering to the specific needs of clients; notably, T7 polymerase emerged as the most preferred type of enzyme being offered in more than 95% mRNA synthesis kits.

9. Presently, close to 115 kits are available in the market for mRNA synthesis; these kits are designed to cater to a wide range of applications, including molecular biology, protein production and vaccine development.

10. mRNA synthesis kits comprise of a variety of components, catering to the specific needs of clients; notably, T7 polymerase emerged as the most preferred type of enzyme being offered in more than 95% mRNA synthesis kits.

11. The rising interest in this market is reflected from the diverse partnerships established among various stakeholders in the recent past; in fact, close to 50% of the deals were inked in the last three years.

12. Various mRNA-based therapeutic / vaccine developers across the world are anticipated to forge strategic alliances with mRNA synthesis and manufacturing service providers to further augment their drug portfolio.

13. Majority (~30%) of the big pharma activities in this domain have been led by Sanofi; of these, most of the initiatives (50%) were instances of partnerships and collaborations inked with various stakeholders active in this domain.

14. Currently, majority of the mRNA synthesis and manufacturing market share is captured by North America; this can be attributed to the advanced healthcare infrastructure, enabling players to conduct extensive research.

15. The infectious diseases sub-segment is estimated to capture most of the overall market share in the current year, owing to the effectiveness of mRNA therapeutics and vaccines in the treatment of such diseases.

16. North America is expected to capture a significant market share of the overall mRNA synthesis and manufacturing market; this trend is unlikely to change in the future.

17. Driven by the rapid success of mRNA-based vaccines and therapeutics developed by prominent players in the US, the mRNA synthesis and manufacturing market is expected to grow at CAGR of 6.5%.

mRNA SYNTHESIS AND MANUFACTURING MARKET: KEY SEGMENTS

Active Pharmaceutical Ingredients Holds the Largest mRNA Synthesis and Manufacturing Market Share

Our estimates suggest that in the current year, the active pharmaceutical ingredients sub-segment is likely to capture majority (>60%) of the mRNA synthesis and manufacturing market share. This can be attributed to the fact that active pharmaceutical ingredients are a fundamental component of any therapeutic / vaccine, that impact the overall efficacy and safety of the product.

Commercial Scale Captures the Largest mRNA Synthesis and Manufacturing Market Share

In the current year, commercial scale sub-segment captures the highest market share (>85%), owing to the commercialization of a large number of mRNA-based therapeutics and vaccines. Further, the market for preclinical and clinical scale is likely to witness a moderate increase during the forecast period. Significant research and development in this field are driving growth in the preclinical and clinical areas, resulting in a rise in the development of mRNA-based products. Additionally, the firms are concentrating on expanding mRNA production facilities to enhance operations at different scales.

Contract Manufacturing is Anticipated to Dominate the mRNA Synthesis and Manufacturing Market

In the current year, the contract manufacturing sub-segment occupies the highest market share (~60%). This dominance is primarily driven by the complexity of mRNA production, which demands specialized expertise and often relies on third-party service providers. Further, the market is likely to witness a substantial increase in the share of in-house manufacturing sub-segment, growing at a CAGR of 7.5% during the forecast period.

Non-COVID-Indications is Likely to Grow at a Notable CAGR During the Forecast Period

The COVID indication sub-segment occupies the highest market share (95%) in the current year. This can be attributed to the fact that mRNA-based products can instruct cells to produce specific pathogen proteins, which in turn trigger a strong and targeted immune response without exposing the individual to the actual pathogen. Further, the market is likely to witness a substantial increase in the share of non-COVID indications, growing at a CAGR of 37.5% during the forecast period.

Focus on Infectious Disease mRNA Therapies

In the current year, the infectious diseases sub-segment occupies the highest market share (~95%), given the fact that mRNA therapeutics and vaccines demonstrated tremendous success in combating the COVID-19 pandemic. Further, the oncology segment is likely to witness significant market growth owing to the increasing prevalence of cancer and the need to develop novel therapeutic options to treat oncological disorders efficiently.

mRNA Vaccines Holds the Largest mRNA Synthesis and Manufacturing Market Share

In the current year, the market is solely driven by mRNA vaccines sub-segment as per mRNA synthesis and manufacturing market forecast, given their proven clinical success, broad preventive applications and flexible nature. Further, the market is likely to witness a substantial increase in the share of mRNA therapeutics, growing at a CAGR of 61.1% during the forecast period. This is because of their rapidly expanding therapeutic applications for therapeutic areas such as oncological, genetic, autoimmune and cardiovascular disorders, thus generating a strong clinical momentum for mRNA therapeutics.

North America to Propel in the mRNA Synthesis and Manufacturing Sector in the Coming Years

North America is likely to capture majority share (>40%) of the market. In addition, the market in North America is expected to grow at a CAGR of 6.6%, during the forecast period. This is because of the advanced healthcare infrastructure in North America, enabling several players in the industry to conduct extensive research and develop novel mRNA modalities for a wide array of therapeutic indications.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

Chief Executive Officer, Mid-sized Organization, Belgium
Chief Commercial Officer, Mid-sized Organization, France
Business Development Manager, Mid-sized Organization, Spain
Team Leader, Large Organization, South Korea

In addition, the market report includes transcripts of the following other third-party discussions:

Scientist in Nucleic Acid Therapeutics, Very Large Organization, United States
Senior Product Manager, Very Large Organization, United States
NEB RNA Research Senior Scientist, Large Organization, United States
Professor and Director of the BASE facility and, Associate Professor and Deputy Director of the BASE facility, Vert Large Organization, Australia

Example Players in the mRNA Synthesis and Manufacturing Market

Aldevron
APExBIO
Aurigene Pharmaceutical Services
BioCell
Biomay
BioNTech
Biorbyt
CELLSCRIPT
Creative Biogene
Curia
Eurogentec
GenScript
eJena Bioscience
Lonza
Merck
Porton Advanced
Revolution Biotechnology
Samsung Biologics
ST Pharm
Thermo Fisher Scientific
TriLink BioTechnologies
Vernal Biosciences
WuXi Biologics
YXgene

mRNA SYNTHESIS AND MANUFACTURING MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the mRNA synthesis and manufacturing market, focusing on key market segments, including [A] type of product, [B] scale of operation, [C] synthesis and manufacturing activity, [D] indication type, [E] therapeutic area, [F] application area and [G] geographical regions.
Market Landscape 1: A detailed assessment of companies offering mRNA custom synthesis services, based on several relevant parameters, including [A] year of establishment, [B] company size, [C] location of the headquarters, [D] type of service offered, [E] type of starting material, [F] structural modification, [G] type of purification method, [H] scale of operation, [I] application area and [J] GMP compliance.
Company Competitiveness Analysis: A competitiveness analysis of mRNA custom synthesis service providers, based on [A] supplier strength, and [A] service strength
Market Landscape 2: A comprehensive assessment of the mRNA contract manufacturing service providers, based on [A] year of establishment, [B] company size, [C] location of the headquarters, [D] location of manufacturing facilities, [E] type of product, [F] type of additional services offered, [G] scale of operation, [H] GMP compliance.
Company Competitiveness Analysis: In-depth company competitiveness analysis of mRNA contract manufacturing service providers based on [A] supplier strength and [B] service strength.
Market Landscape 3: A detailed assessment of the current market landscape of mRNA synthesis kits based on several relevant parameters, such as [A] kit, [B] type of enzyme, [C] type of enzyme mix used, [D] type of mRNA component modified, [E] number of reactions, [F] yield per reaction, [G] reaction run-time and shelf life, [H] year of establishment, [I] company size, [J] location of the headquarters and [K] most active players.
Product Competitive Analysis: An insightful analysis of mRNA synthesis kits, based on [A] developer strength and [B] product portfolio strength.
Company Profiles: In-depth profiles of prominent players across North America, Europe and Asia-Pacific, focusing on [A] year of establishment, [B] location of headquarters, [C] B-mRNA synthesis service portfolio, [D] recent developments and [E] an informed future outlook.
Partnerships and Collaborations: A detailed analysis of the partnerships inked between stakeholders engaged in this industry, based on several parameters, such as [A] year of partnership, [A] type of partnership, [B] type of product, [C] type of partner and [D] most active players.
Likely Partner Analysis: a comprehensive analysis of mRNA-based therapeutics / vaccines developers that are likely to partner with mRNA contract manufacturing service providers.
Big Pharma Initiatives: A review of the various mRNA-focused initiatives undertaken by big players, highlighting trends across various parameters, such as [A] number of initiatives, [A] year of initiative, [A] type of partnership, [B] type of expansion, [C] region of expansion, [D] type of pharmaceutical and [E] therapeutic area.
Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the mRNA synthesis and manufacturing market. It also features identification and market analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What is the current global capacity of developers?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. BACKGROUND

1.1. Context
1.2. Project Objectives

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Overview of mRNA
6.2. Structure of mRNA
6.3. Evolution of mRNA Vaccines
6.4. Types of mRNA Synthesis Processes
- 6.4.1. Chemical Synthesis of mRNA
- 6.4.2. In vitro Synthesis of mRNA
6.5. Applications of mRNA
6.6. Challenges Associated with mRNA Synthesis
6.7. Commonly Outsourced mRNA Manufacturing Operations
6.8. Advantages of Outsourcing Manufacturing Operations
6.9. Conclusion

7. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: MARKET LANDSCAPE

7.1. Overview of mRNA Custom Synthesis Service Providers
- 7.1.1. Analysis by Year of Establishment
- 7.1.2. Analysis by Company Size
- 7.1.3. Analysis by Location of Headquarters
- 7.1.4. Analysis by Company Size and Location of Headquarters
- 7.1.5. Analysis by Type of Service Offered
- 7.1.6. Analysis by Type of Starting Material
- 7.1.7. Analysis by Structural Modification
- 7.1.8. Analysis by Type of Purification Method
- 7.1.9. Analysis by Scale of Operation
- 7.1.10. Analysis by Application Area
- 7.1.11. Analysis by GMP Compliance

8. COMPANY COMPETITIVENESS ANALYSIS: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

8.1. Methodology and Key Parameters
8.2. Scoring Criteria
8.3. Overview of Peer Groups
8.4. Company Competitiveness Analysis
- 8.4.1. Competitiveness Analysis of Service Providers headquartered in North America: 2D Dot Plot
- 8.4.2. Leading Service Providers headquartered in North America: Spider Web Analysis
- 8.4.3. Competitiveness Analysis of Service Providers headquartered in Europe: 2D Dot Plot
- 8.4.4. Leading Service Providers headquartered in Europe: Spider Web Analysis
- 8.4.5. Competitiveness Analysis of Service Providers headquartered in Asia-Pacific: 2D Dot Plot
- 8.4.6. Leading Service Providers headquartered in Asia-Pacific: Spider Web Analysis

9. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE

9.1. Overview of mRNA Contract Manufacturing Service Providers
- 9.1.1. Analysis by Year of Establishment
- 9.1.2. Analysis by Company Size
- 9.1.3. Analysis by Location of Headquarters (Region)
- 9.1.4. Analysis by Location of Headquarters (Country)
- 9.1.5. Analysis by Location of Manufacturing Facilities
- 9.1.6. Analysis by Type of Product Manufactured
- 9.1.7. Analysis by GMP Compliance
- 9.1.8. Analysis by Scale of Operation
- 9.1.9. Analysis by Type of Additional Services Offered

10. COMPANY COMPETITIVENESS ANALYSIS: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

10.1. Methodology and Key Parameters
10.2. Scoring Criteria
10.3. Overview of Peer Groups
10.4. Company Competitiveness Analysis
- 10.4.1. Competitiveness Analysis of Service Providers headquartered in North America: 2D Dot Plot
- 10.4.2. Leading Service Providers headquartered in North America: Spider Web Analysis
- 10.4.3. Competitiveness Analysis of Service Providers headquartered in Europe: 2D Dot Plot
- 10.4.4. Leading Service Providers headquartered in Europe: Spider Web Analysis
- 10.4.5. Competitiveness Analysis of Service Providers headquartered in Asia-Pacific: 2D Dot Plot
- 10.4.6. Leading Service Providers headquartered in Asia-Pacific: Spider Web Analysis

11. mRNA SYNTHESIS KITS: MARKET LANDSCAPE

11.1. Overview of mRNA Synthesis Kits
- 11.1.1. Analysis by Kit Components
- 11.1.2. Analysis by Type of Enzyme
- 11.1.3. Analysis by Type of Enzyme Mix Used
- 11.1.4. Analysis by mRNA Component Modified
- 11.1.5. Analysis by Number of Reactions
- 11.1.6. Analysis by Yield per Reaction
- 11.1.7. Analysis by Reaction Run-time
- 11.1.8. Analysis by Shelf Life
11.2. mRNA Synthesis Kits: Developers Landscape
- 11.2.1. Analysis by Year of Establishment
- 11.2.2. Analysis by Company Size
- 11.2.3. Analysis by Location of Headquarters
- 11.2.4. Most Active Players: Analysis by Number of Kits Developed

12. PRODUCT COMPETITIVENESS ANALYSIS: mRNA SYNTHESIS KITS

12.1. Methodology and Key Parameters
12.2. Scoring Criteria
12.3. Leading mRNA Synthesis Kits: 2D Dot Plot

13. COMPANY PROFILES: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

13.1. Methodology
13.2. Aldevron
- 13.2.1. Company Details
- 13.2.2. Service Portfolio
- 13.2.3. Financial Information
- 13.2.4. Future Outlook
13.3. Thermo Fischer Scientific
13.4. Revolution Biomanufacturing
13.5. BioNTech
13.6. Eurogentec
13.7. Biocell
13.8. YXgene
13.9. Aurigene Pharmaceutical Services
13.10. Biomay
13.11. GenScript
13.12. Trilink Biotechnologies

14. COMPANY PROFILES: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

14.1. Methodology
14.2. Curia
- 14.2.1. Company Details
- 14.2.2. Service Portfolio
- 14.2.3. Financial Information
- 14.2.4. Future Outlook
14.3. Lonza
14.4. Merck
14.5. Porton Advanced
14.6. Samsung Biologics
14.7. ST Pharm
14.8. Vernal Biosciences
14.9. Wuxi Biologics

15. COMPANY PROFILES: mRNA SYNTHESIS KITS

15.1. Methodology
15.2. APExBIO
- 15.2.1. Company Details
- 15.2.2. mRNA Synthesis Kits Portfolio
15.3. Biorbyt
15.4. Cell Script
15.5. Creative Biogene
15.6. Jena Bioscience
15.7. Thermo Fischer Scientific

16. PARTNERSHIPS AND COLLABORATIONS

16.1. Partnership Models
16.2. mRNA Synthesis and Manufacturing Market: Partnerships and Collaborations
- 16.2.1. Analysis by Year of Partnership
- 16.2.2. Analysis by Type of Partnership
- 16.2.3. Analysis by Year and Type of Partnership
- 16.2.4. Analysis by Type of Partner
- 16.2.5. Analysis by Type of Pharmaceutical
- 16.2.6. Analysis by Type of Drug Product
- 16.2.7. Most Active Players: Analysis by Number of Partnerships
- 16.2.8. Analysis by Geography
  - 16.2.8.1. Local and International Deals
  - 16.2.8.2. Intracontinental and Intercontinental Deals

17. LIKELY PARTNER ANALYSIS

17.1. mRNA Synthesis and Manufacturing Market: Likely Partner Analysis
17.2. Methodology and Key Parameters
17.3. Scoring Criteria
17.4. mRNA Drug Developers: Likely Partners based in North America
- 17.4.1. mRNA Drug Developers: Most Likely Partners based in North America
17.5. mRNA Drug Developers: Likely Partners based in Europe
- 17.5.1. mRNA Drug Developers: Most Likely Partners based in Europe
17.6. mRNA Drug Developers: Likely Partners based in Asia-Pacific and Rest of the World
- 17.6.1. mRNA Drug Developers: Most Likely Partners based in Asia-Pacific and Rest of the World

18. BIG PLAYER INITIATIVES

18.1. Methodology
18.2. Key Initiatives Analyzed
18.3. mRNA Synthesis and Manufacturing Market: Big Player Initiatives
- 18.3.1. Analysis by Year of Initiative
- 18.3.2. Analysis by Type of Initiative
- 18.3.3. Analysis by Year and Type of Initiative
- 18.3.4. Big Players: Analysis by Number of Initiatives
- 18.3.5. Big Players: Analysis by Type of Initiative
- 18.3.6. Analysis by Type of Pharmaceutical
- 18.3.7. Analysis by Therapeutic Area
- 18.3.8. Big Players: Analysis by Number of Partnerships
- 18.3.9. Analysis by Type of Partnership
- 18.3.10. Big Players: Analysis by Number of Expansions
- 18.3.11. Analysis by Type of Expansion
- 18.3.12. Big Players: Analysis by Region of Expansion

19. MARKET IMPACT ANALYSIS

19.1. Market Drivers
19.2. Market Restraints
19.3. Market Opportunities
19.4. Market Challenges

20. GLOBAL mRNA SYNTHESIS AND MANUFACTURING MARKET

20.1. Key Assumptions and Methodology
20.2. Global mRNA Synthesis and Manufacturing Market: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 20.2.1. Scenario Analysis
  - 20.2.1.1. Conservative Scenario
  - 20.2.1.2. Optimistic Scenario
20.3. Comparison with Previous Edition
20.4. Key Market Segmentations

21. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY TYPE OF PRODUCT

21.1. Methodology
21.2. mRNA Synthesis and Manufacturing Market: Distribution by Type of Product
- 21.2.1. mRNA Synthesis and Manufacturing Market for Active Pharmaceutical Ingredients: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 21.2.2. mRNA Synthesis and Manufacturing Market for Finished Dose Formulations: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

22. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY SCALE OF OPERATION

22.1. Methodology
22.2. mRNA Synthesis and Manufacturing Market: Distribution by Scale of Operation
- 22.2.1. mRNA Synthesis and Manufacturing Market for Preclinical and Clinical Scale: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 22.2.2. mRNA Synthesis and Manufacturing Market for Commercial Scale: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

23. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY SYNTHESIS AND MANUFACTURING ACTIVITY

23.1. Methodology
23.2. mRNA Synthesis and Manufacturing Market: Distribution by Synthesis and Manufacturing Activity
- 23.2.1. mRNA Synthesis and Manufacturing Market for Contract Manufacturing: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 23.2.2. mRNA Synthesis and Manufacturing Market for In-house Manufacturing: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

24. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY INDICATION TYPE

24.1. Methodology
24.2. mRNA Synthesis and Manufacturing Market: Distribution by Indication Type
- 24.2.1. mRNA Synthesis and Manufacturing Market for COVID Indications: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 24.2.2. mRNA Synthesis and Manufacturing Market for Non-COVID Indications: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

25. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY THERAPEUTIC AREA

25.1. Methodology
25.2. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area
- 25.2.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 25.2.2. mRNA Synthesis and Manufacturing Market for Oncological Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 25.2.3. mRNA Synthesis and Manufacturing Market for Other Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

26. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY APPLICATION AREA

26.1. Methodology
26.2. mRNA Synthesis and Manufacturing Market: Distribution by Application Area
- 26.2.1. mRNA Synthesis and Manufacturing Market for mRNA Vaccines: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.2.2. mRNA Synthesis and Manufacturing Market for mRNA Therapeutics: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS

27.1. Methodology
27.2. mRNA Synthesis and Manufacturing Market: Distribution by Geographical Regions
- 27.2.1. mRNA Synthesis and Manufacturing Market in North America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.2.1.1. mRNA Synthesis and Manufacturing Market in the US: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.2.1.2. mRNA Synthesis and Manufacturing Market in Canada: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.3.1. mRNA Synthesis and Manufacturing Market in Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.1. mRNA Synthesis and Manufacturing Market in Germany: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.2. mRNA Synthesis and Manufacturing Market in France: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.3. mRNA Synthesis and Manufacturing Market in the UK: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.4. mRNA Synthesis and Manufacturing Market in Italy: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.5. mRNA Synthesis and Manufacturing Market in Spain: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.6. mRNA Synthesis and Manufacturing Market in Rest of Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.4.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.4.1.1. mRNA Synthesis and Manufacturing Market in China: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.4.1.2. mRNA Synthesis and Manufacturing Market in India: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.4.1.3. mRNA Synthesis and Manufacturing Market in Japan: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.4.1.4. mRNA Synthesis and Manufacturing Market in South Korea: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.4.1.5. mRNA Synthesis and Manufacturing Market in Rest of Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.5.1. mRNA Synthesis and Manufacturing Market in Latin America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.5.1.1. mRNA Synthesis and Manufacturing Market in Brazil: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.5.1.2. mRNA Synthesis and Manufacturing Market in Argentina: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.6.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.6.1.1. mRNA Synthesis and Manufacturing Market in Saudi Arabia: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.6.1.2. mRNA Synthesis and Manufacturing Market in Israel: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.6.1.3. mRNA Synthesis and Manufacturing Market in United Arab Emirates: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.6.1.4. mRNA Synthesis and Manufacturing Market in Rest of Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

28.1. mRNA Synthesis and Manufacturing Market in North America: Distribution by Type of Product
- 28.1.1. mRNA Synthesis and Manufacturing Market in North America for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.1.2. mRNA Synthesis and Manufacturing Market in North America for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.2. mRNA Synthesis and Manufacturing Market in North America: Distribution by Scale of Operation
- 28.2.1. mRNA Synthesis and Manufacturing Market in North America for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.2.2. mRNA Synthesis and Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3. mRNA Synthesis and Manufacturing Market in North America: Distribution by Synthesis and Manufacturing Activity
- 28.3.1. mRNA Synthesis and Manufacturing Market in North America for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.3.2. mRNA Synthesis and Manufacturing Market in North America for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.4. mRNA Synthesis and Manufacturing Market in North America: Distribution by Indication Type
- 28.4.1. mRNA Synthesis and Manufacturing Market in North America for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.4.2. mRNA Synthesis and Manufacturing Market in North America for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.5. mRNA Synthesis and Manufacturing Market in North America: Distribution by Therapeutic Area
- 28.5.1. mRNA Synthesis and Manufacturing Market in North America for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.5.2. mRNA Synthesis and Manufacturing Market in North America for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.5.3. mRNA Synthesis and Manufacturing Market in North America for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.6. mRNA Synthesis and Manufacturing Market in North America: Distribution by Application Area
- 28.6.1. mRNA Synthesis and Manufacturing Market in North America for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.6.2. mRNA Synthesis and Manufacturing Market in North America for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29. MARKET OPPORTUNITY ANALYSIS: EUROPE

29.1. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Type of Product
- 29.1.1. mRNA Synthesis and Manufacturing Market in Europe for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.1.2. mRNA Synthesis and Manufacturing Market in Europe for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.2. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Scale of Operation
- 29.2.1. mRNA Synthesis and Manufacturing Market in Europe for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.2.2. mRNA Synthesis and Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.3. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Synthesis and Manufacturing Activity
- 29.3.1. mRNA Synthesis and Manufacturing Market in Europe for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.3.2. mRNA Synthesis and Manufacturing Market in Europe for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.4. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Indication Type
- 29.4.1. mRNA Synthesis and Manufacturing Market in Europe for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.4.2. mRNA Synthesis and Manufacturing Market in Europe for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.5. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Therapeutic Area
- 29.5.1. mRNA Synthesis and Manufacturing Market in Europe for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.5.2. mRNA Synthesis and Manufacturing Market in Europe for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.5.3. mRNA Synthesis and Manufacturing Market in Europe for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.6. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Application Area
- 29.6.1. mRNA Synthesis and Manufacturing Market in Europe for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.6.2. mRNA Synthesis and Manufacturing Market in Europe for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

30.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Type of Product
- 30.1.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.1.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
- 30.2.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.2.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Synthesis and Manufacturing Activity
- 30.3.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.3.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.4. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Indication Type
- 30.4.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.4.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.5. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
- 30.5.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.5.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.5.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.6. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Application Area
- 30.6.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.6.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31. MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

31.1. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Type of Product
- 31.1.1. mRNA Synthesis and Manufacturing Market in Latin America for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.1.2. mRNA Synthesis and Manufacturing Market in Latin America for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.2. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Scale of Operation
- 31.2.1. mRNA Synthesis and Manufacturing Market in Latin America for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.2.2. mRNA Synthesis and Manufacturing Market in Latin America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.3. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Synthesis and Manufacturing Activity
- 31.3.1. mRNA Synthesis and Manufacturing Market in Latin America for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.3.2. mRNA Synthesis and Manufacturing Market in Latin America for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.4. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Indication Type
- 31.4.1. mRNA Synthesis and Manufacturing Market in Latin America for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.4.2. mRNA Synthesis and Manufacturing Market in Latin America for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.5. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Therapeutic Area
- 31.5.1. mRNA Synthesis and Manufacturing Market in Latin America for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.5.2. mRNA Synthesis and Manufacturing Market in Latin America for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.5.3. mRNA Synthesis and Manufacturing Market in Latin America for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.6. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Application Area
- 31.6.1. mRNA Synthesis and Manufacturing Market in Latin America for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.6.2. mRNA Synthesis and Manufacturing Market in Latin America for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

32.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Type of Product
- 32.1.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.1.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Scale of Operation
- 32.2.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.2.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.3. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Synthesis and Manufacturing Activity
- 32.3.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.3.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.4. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Indication Type
- 32.4.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.4.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.5. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Therapeutic Area
- 32.5.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.5.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.5.3. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.6. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Application Area
- 32.6.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.6.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
*Detailed information on Chapter 28 to 32 is available in the Excel Data Packs shared along with the report**

33. CONCLUDING INSIGHTS

34. EXECUTIVE INSIGHTS

35. APPENDIX I: TABULATED DATA

36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

簡介目錄圖表

List of Tables

Table 7.1 List of mRNA Custom Synthesis Service Providers
Table 9.1 List of mRNA Contract Manufacturing Service Providers
Table 11.1 List of mRNA Synthesis Kits
Table 11.2 List of mRNA Synthesis Kit Developers
Table 12.1 Aldevron: Service Portfolio
Table 12.2 Aldevron: Recent Developments and Future Outlook
Table 12.3 Thermo Fischer Scientific: Service Portfolio
Table 12.4 Thermo Fischer Scientific: Recent Developments and Future Outlook
Table 12.5 Revolution Biomanufacturing: Service Portfolio
Table 12.6 Revolution Biomanufacturing: Recent Developments and Future Outlook
Table 12.7 BioNTech: Service Portfolio
Table 12.8 BioNTech: Recent Developments and Future Outlook
Table 12.9 Eurogentec: Service Portfolio
Table 12.10 Eurogentec: Recent Developments and Future Outlook
Table 12.11 Biocell: Service Portfolio
Table 12.12 Biocell: Recent Developments and Future Outlook
Table 12.13 YXgene: Service Portfolio
Table 12.14 YXgene: Recent Developments and Future Outlook
Table 13.1 Curia: Service Portfolio
Table 13.2 Curia: Recent Developments and Future Outlook
Table 13.3 Lonza: Service Portfolio
Table 13.4 Lonza: Recent Developments and Future Outlook
Table 13.5 Merck: Service Portfolio
Table 13.6 Merck: Recent Developments and Future Outlook
Table 13.7 Porton Advanced: Service Portfolio
Table 13.8 Porton Advanced: Recent Developments and Future Outlook
Table 13.9 Samsung Biologics: Service Portfolio
Table 13.10 Samsung Biologics: Recent Developments and Future Outlook
Table 13.11 ST Pharm: Service Portfolio
Table 13.12 ST Pharm: Recent Developments and Future Outlook
Table 13.13 Vernal Biosciences: Service Portfolio
Table 13.14 Vernal Biosciences: Recent Developments and Future Outlook
Table 13.13 Wuxi Biologics: Service Portfolio
Table 13.14 Wuxi Biologics: Recent Developments and Future Outlook
Table 14.1 APExBIO: mRNA Synthesis Kits Portfolio
Table 14.2 Biorbyt: mRNA Synthesis Kits Portfolio
Table 14.3 Cell Script: mRNA Synthesis Kits Portfolio
Table 14.4 Creative Biogene: mRNA Synthesis Kits Portfolio
Table 14.5 Jena Bioscience: mRNA Synthesis Kits Portfolio
Table 14.6 Thermo Fischer Scientific: mRNA Synthesis Kits Portfolio
Table 15.1 mRNA Synthesis and Manufacturing: List of Partnerships and Collaborations, since 2019
Table 15.2 mRNA Synthesis and Manufacturing: Information on Location of Headquarters (Country / Region) and Type of Agreement (Intercontinental / Intracontinental)
Table 16.1 mRNA Drug Developers: Potential Strategic Partners in North America
Table 16.2 Most Likely Partner
Table 17.1 Big Player Initiatives: List of mRNA Synthesis and Manufacturing Focused Initiatives, since 2019
Table 35.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
Table 35.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
Table 35.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
Table 35.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters
Table 35.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service Offered
Table 35.6 mRNA Custom Synthesis Service Providers: Distribution by Starting Material
Table 35.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
Table 35.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method
Table 35.9 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation
Table 35.10 mRNA Custom Synthesis Service Providers: Distribution by Application Area
Table 35.11 mRNA Custom Synthesis Service Providers: Distribution by GMP Compliance
Table 35.12 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
Table 35.13 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
Table 35.14 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Region)
Table 35.15 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Country)
Table 35.16 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Table 35.17 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product Manufactured
Table 35.18 mRNA Contract Manufacturing Service Providers: Distribution by GMP Compliance
Table 35.19 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation
Table 35.20 mRNA Contract Manufacturing Service Providers: Distribution by Type of Additional Services Offered
Table 35.21 mRNA Synthesis Kits: Distribution by Kit Components
Table 35.22 mRNA Synthesis Kits: Distribution by Type of Enzyme
Table 35.23 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
Table 35.24 mRNA Synthesis Kits: Distribution by mRNA Component Modified
Table 35.25 mRNA Synthesis Kits: Distribution by Number of Reactions
Table 35.26 mRNA Synthesis Kits: Distribution by Yield Per Reaction
Table 35.27 mRNA Synthesis Kits: Distribution by Reaction Run Time
Table 35.28 mRNA Synthesis Kits: Distribution by Shelf Life
Table 35.29 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
Table 35.30 mRNA Synthesis Kit Providers: Distribution by Company Size
Table 35.31 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
Table 35.32 Most Active Players: Distribution by Number of Kits Developed
Table 35.33 Danaher: Annual Revenues, Since FY 2021 (USD Billion)
Table 35.34 Thermo Fischer Scientific: Annual Revenues, Since FY 2021 (USD Billion)
Table 35.35 BioNTech: Annual Revenues, Since FY 2021 (EUR Billion)
Table 35.36 Kaneka: Annual Revenues, Since FY 2021 (JPY Billion)
Table 35.37 Lonza: Annual Revenues, Since FY 2021 (CHF Billion)
Table 35.38 Merck: Annual Revenues, Since FY 2021 (EUR Billion)
Table 35.39 Samsung Biologics: Annual Revenues, Since FY 2021 (KRW Trillion)
Table 35.40 ST Pharm: Annual Revenues, Since FY 2021 (KRW Billion)
Table 35.41 Wuxi Biologics: Annual Revenues, Since FY 2020 (RMB Billion)
Table 35.42 Partnerships and Collaborations: Distribution by Year of Partnership
Table 35.43 Partnerships and Collaborations: Distribution by Type of Partnership
Table 35.44 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 35.45 Partnerships and Collaborations: Distribution by Type of Partner
Table 35.46 Partnerships and Collaborations: Distribution by Type of Pharmaceutical
Table 35.47 Partnerships and Collaborations: Distribution by Type of Drug Product
Table 35.48 Most Active Players: Distribution by Number of Partnerships
Table 35.49 Partnerships and Collaborations: Local and International Deals
Table 35.50 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 35.51 Big Player Initiatives: Distribution by Year of Initiative
Table 35.52 Big Player Initiatives: Distribution by Type of Initiative
Table 35.53 Big Player Initiatives: Distribution by Year and Type of Initiative
Table 35.54 Big Player Initiatives: Distribution of Player by Number of Initiatives
Table 35.55 Big Player Initiatives: Distribution of Player by Type of Initiative
Table 35.56 Big Player Initiatives: Distribution by Type of Pharmaceutical
Table 35.57 Big Player Initiatives: Distribution by Therapeutic Area
Table 35.58 Big Player Initiatives: Distribution of Player by Number of Partnerships
Table 35.59 Big Player Initiatives: Distribution by Type of Partnership
Table 35.60 Big Player Initiatives: Distribution of Player by Number of Expansions
Table 35.61 Big Player Initiatives: Distribution by Type of Expansion
Table 35.62 Big Player Initiatives: Distribution of Player by Region of Expansion
Table 35.63 Global mRNA Synthesis and Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.64 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario
Table 35.65 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario
Table 35.66 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product
Table 35.67 mRNA Synthesis and Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.68 mRNA Synthesis and Manufacturing Market for Finished Dose Formulations, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.69 mRNA Synthesis and Manufacturing Market: Distribution by Scale of Operation
Table 35.70 mRNA Synthesis and Manufacturing Market for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.71 mRNA Synthesis and Manufacturing Market for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.72 mRNA Synthesis and Manufacturing Market: Distribution by Synthesis and Manufacturing Activity
Table 35.73 mRNA Synthesis and Manufacturing Market for Commercial Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.74 mRNA Synthesis and Manufacturing Market for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.75 mRNA Synthesis and Manufacturing Market: Distribution by Type of Indication
Table 35.76 mRNA Synthesis and Manufacturing Market for COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.77 mRNA Synthesis and Manufacturing Market for Non-COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.78 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area
Table 35.79 mRNA Synthesis and Manufacturing Market for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.80 mRNA Synthesis and Manufacturing Market for Oncological Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.81 mRNA Synthesis and Manufacturing Market for Other Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.82 mRNA Synthesis and Manufacturing Market: Distribution by Application Area
Table 35.83 mRNA Synthesis and Manufacturing Market for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.84 mRNA Synthesis and Manufacturing Market for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.85 mRNA Synthesis and Manufacturing Market: Distribution by Geographical Region
Table 35.86 mRNA Synthesis and Manufacturing Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.87 mRNA Synthesis and Manufacturing Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.88 mRNA Synthesis and Manufacturing Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.89 mRNA Synthesis and Manufacturing Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.90 mRNA Synthesis and Manufacturing Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.91 mRNA Synthesis and Manufacturing Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.92 mRNA Synthesis and Manufacturing Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.93 mRNA Synthesis and Manufacturing Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.94 mRNA Synthesis and Manufacturing Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.95 mRNA Synthesis and Manufacturing Market in rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.96 mRNA Synthesis and Manufacturing Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.97 mRNA Synthesis and Manufacturing Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.98 mRNA Synthesis and Manufacturing Market in India, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.99 mRNA Synthesis and Manufacturing Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.100 mRNA Synthesis and Manufacturing Market in South Korea, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.101 mRNA Synthesis and Manufacturing Market in rest of Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.102 mRNA Synthesis and Manufacturing Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.103 mRNA Synthesis and Manufacturing Market in Brazil, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.104 mRNA Synthesis and Manufacturing Market in Argentina, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.105 mRNA Synthesis and Manufacturing Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.106 mRNA Synthesis and Manufacturing Market in Saudi Arabia, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.107 mRNA Synthesis and Manufacturing Market in Israel, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.108 mRNA Synthesis and Manufacturing Market in United Arab Emirates, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 35.109 mRNA Synthesis and Manufacturing Market in rest of Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Structure of mRNA
Figure 6.2 Evolution of mRNA Vaccines
Figure 6.3 Chemical Synthesis
Figure 6.4 In-vitro Synthesis
Figure 6.5 Applications of mRNA
Figure 6.6 Advantages of Outsourcing Manufacturing Operations
Figure 7.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
Figure 7.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
Figure 7.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
Figure 7.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters
Figure 7.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service Offered
Figure 7.6 mRNA Custom Synthesis Service Providers: Distribution by Starting Material
Figure 7.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
Figure 7.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method
Figure 7.9 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation
Figure 7.10 mRNA Custom Synthesis Service Providers: Distribution by Application Area
Figure 7.11 mRNA Custom Synthesis Service Providers: Distribution by GMP Compliance
Figure 8.1 Company Competitiveness Analysis: Service Providers based in North America
Figure 8.2 Company Competitiveness Analysis: Service Providers based in Europe
Figure 8.3 Company Competitiveness Analysis: Service Providers based in Asia-Pacific
Figure 9.1 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
Figure 9.2 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
Figure 9.3 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Region)
Figure 9.4 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Country)
Figure 9.5 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Figure 9.6 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product Manufactured
Figure 9.7 mRNA Contract Manufacturing Service Providers: Distribution by GMP Compliance
Figure 9.8 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation
Figure 9.9 mRNA Contract Manufacturing Service Providers: Distribution by Type of Additional Services Offered
Figure 10.1 Company Competitiveness Analysis: Service Providers based in North America
Figure 10.2 Company Competitiveness Analysis: Service Providers based in Europe
Figure 10.3 Company Competitiveness Analysis: Service Providers based in Asia-Pacific
Figure 11.1 mRNA Synthesis Kits: Distribution by Kit Components
Figure 11.2 mRNA Synthesis Kits: Distribution by Type of Enzyme
Figure 11.3 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
Figure 11.4 mRNA Synthesis Kits: Distribution by mRNA Component Modified
Figure 11.5 mRNA Synthesis Kits: Distribution by Number of Reactions
Figure 11.6 mRNA Synthesis Kits: Distribution by Yield Per Reaction
Figure 11.7 mRNA Synthesis Kits: Distribution by Reaction Run Time
Figure 11.8 mRNA Synthesis Kits: Distribution by Shelf Life
Figure 11.9 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
Figure 11.10 mRNA Synthesis Kit Providers: Distribution by Company Size
Figure 11.11 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
Figure 11.12 Most Active Players: Distribution by Number of Kits Developed
Figure 12.1 mRNA Synthesis Kits: 2D Dot Plot
Figure 13.1 Danaher: Annual Revenues, Since FY 2021 (USD Billion)
Figure 13.2 Thermo Fischer Scientific: Annual Revenues, Since FY 2021 (USD Billion)
Figure 13.3 BioNTech: Annual Revenues, Since FY 2021 (EUR Billion)
Figure 13.4 Eurogentec: Annual Revenues, Since FY 2021 (JPY Billion)
Figure 14.1 Lonza: Annual Revenues, Since FY 2021 (CHF Billion)
Figure 14.2 Merck: Annual Revenues, Since FY 2021 (EUR Billion)
Figure 14.3 Samsung Biologics: Annual Revenues, Since FY 2021 (KRW Trillion)
Figure 14.4 ST Pharm: Annual Revenues, Since FY 2021 (KRW Billion)
Figure 14.5 Wuxi Biologics: Annual Revenues, Since FY 2020 (RMB Billion)
Figure 16.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 16.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 16.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 16.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 16.5 Partnerships and Collaborations: Distribution by Type of Pharmaceutical
Figure 16.6 Partnerships and Collaborations: Distribution by Type of Drug Product
Figure 16.7 Most Active Players: Distribution by Number of Partnerships
Figure 16.8 Partnerships and Collaborations: Local and International Deals
Figure 16.9 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 18.1 Big Player Initiatives: Distribution by Year of Initiative
Figure 18.2 Big Player Initiatives: Distribution by Type of Initiative
Figure 18.3 Big Player Initiatives: Distribution by Year and Type of Initiative
Figure 18.4 Big Player Initiatives: Distribution of Player by Number of Initiatives
Figure 18.5 Big Player Initiatives: Distribution of Player by Type of Initiative
Figure 18.6 Big Player Initiatives: Distribution by Type of Pharmaceutical
Figure 18.7 Big Player Initiatives: Distribution by Therapeutic Area
Figure 18.8 Big Player Initiatives: Distribution of Player by Number of Partnerships
Figure 18.9 Big Player Initiatives: Distribution by Type of Partnership
Figure 18.10 Big Player Initiatives: Distribution of Player by Number of Expansions
Figure 18.11 Big Player Initiatives: Distribution by Type of Expansion
Figure 18.12 Big Player Initiatives: Distribution of Player by Region of Expansion
Figure 19.1. Market Trends and Outlook: Market Drivers
Figure 19.2. Market Trends and Outlook: Market Restraints
Figure 19.3. Market Trends and Outlook: Market Opportunities
Figure 19.4. Market Trends and Outlook: Market Challenges
Figure 20.1 Global mRNA Synthesis and Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 20.2 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario
Figure 20.3 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario
Figure 21.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product
Figure 21.2 mRNA Synthesis and Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 21.3 mRNA Synthesis and Manufacturing Market for Finished Dose Formulations, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 22.1 mRNA Synthesis and Manufacturing Market: Distribution by Scale of Operation
Figure 22.2 mRNA Synthesis and Manufacturing Market for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 22.3 mRNA Synthesis and Manufacturing Market for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 23.1 mRNA Synthesis and Manufacturing Market: Distribution by Synthesis and Manufacturing Activity
Figure 23.2 mRNA Synthesis and Manufacturing Market for Commercial Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 23.3 mRNA Synthesis and Manufacturing Market for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 24.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Indication
Figure 24.2 mRNA Synthesis and Manufacturing Market for COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 24.3 mRNA Synthesis and Manufacturing Market for Non-COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 25.1 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area
Figure 25.2 mRNA Synthesis and Manufacturing Market for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 25.3 mRNA Synthesis and Manufacturing Market for Oncological Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 25.4 mRNA Synthesis and Manufacturing Market for Other Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 26.1 mRNA Synthesis and Manufacturing Market: Distribution by Application Area
Figure 26.2 mRNA Synthesis and Manufacturing Market for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 26.3 mRNA Synthesis and Manufacturing Market for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.1 mRNA Synthesis and Manufacturing Market: Distribution by Geographical Region
Figure 27.2 mRNA Synthesis and Manufacturing Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.3 mRNA Synthesis and Manufacturing Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.4 mRNA Synthesis and Manufacturing Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.5 mRNA Synthesis and Manufacturing Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.6 mRNA Synthesis and Manufacturing Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.7 mRNA Synthesis and Manufacturing Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.8 mRNA Synthesis and Manufacturing Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.9 mRNA Synthesis and Manufacturing Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.10 mRNA Synthesis and Manufacturing Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.11 mRNA Synthesis and Manufacturing Market in rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.12 mRNA Synthesis and Manufacturing Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.13 mRNA Synthesis and Manufacturing Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.14 mRNA Synthesis and Manufacturing Market in India, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.15 mRNA Synthesis and Manufacturing Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.16 mRNA Synthesis and Manufacturing Market in South Korea, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.17 mRNA Synthesis and Manufacturing Market in rest of Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.18 mRNA Synthesis and Manufacturing Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.19 mRNA Synthesis and Manufacturing Market in Brazil, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.2 mRNA Synthesis and Manufacturing Market in Argentina, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.21mRNA Synthesis and Manufacturing Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.22 mRNA Synthesis and Manufacturing Market in Saudi Arabia, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.23 mRNA Synthesis and Manufacturing Market in Israel, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.24 mRNA Synthesis and Manufacturing Market in United Arab Emirates, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 27.25 mRNA Synthesis and Manufacturing Market in rest of Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

分子診斷原料酶市場：按技術、酵素類型、最終用戶、應用、組成、國家和地區分類－全球產業分析、市場規模、市場佔有率及2025-2032年預測

mRNA 合成與製造市場分析及預測（至 2034 年）：類型、產品、服務、技術、應用、流程、最終用戶、組件與階段

美國mRNA 合成原料市場規模、佔有率和趨勢分析報告：按類型、應用、最終用途和細分市場預測，2025 年至 2033 年

mRNA合成原料市場規模、佔有率、趨勢分析報告：按類型、應用、最終用途、地區、細分市場預測，2025-2030年

mRNA 合成與製造市場：按服務、按服務類型、按製造流程、按製造規模、按技術、按應用、按用途、按最終用戶 - 2025 年至 2030 年全球預測

全球 mRNA 合成與製造市場（按產品、應用、最終用戶、服務和地區分類）- 2029 年預測

mRNA生酵素的全球市場:實際成果與預測(2019年～2030年)

FAQ

mRNA合成與生產市場：產業趨勢及全球預測（至2035年）－依產品、企業規模、合成與生產活動、適應症類型、治療領域、應用領域及地區劃分

mRNA Synthesis and Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Product, Scale of Operation, Synthesis and Manufacturing Activity, Indication Type, Therapeutic Area, Application Area and Geographical Regions

mRNA合成與生產市場：概論

mRNA 合成與生產市場：成長與趨勢

mRNA合成與生產市場：主要發現

在當前市場格局中，全球約有 55 家供應商聲稱提供客製化 mRNA 合成服務，其中 60% 的總部位於北美。

2. 大多數 mRNA 客製化合成服務提供者（約 95%）提供 mRNA 的 5' 端修飾。這主要是為了提高 mRNA 的穩定性、翻譯效率並降低免疫原性風險。

3. 各利益相關者正在積極提升現有能力，以增強其產品組合，並在 mRNA 定制合成領域獲得相對於其他公司的競爭優勢。

4. 隨著對mRNA疫苗的需求不斷增長，以及mRNA合成和生產技術的進步，目前約有45家公司積極提供mRNA合約生產服務。

5. 約60%的公司提供mRNA原料藥和製劑的合約生產服務，約90%的公司提供臨床規模的mRNA合約生產服務。

6. mRNA合約生產服務提供者正積極拓展和豐富其mRNA生產能力，以增強其服務組合併建立具有競爭力的市場基礎。

7. 目前市面上約有115種mRNA合成試劑盒，適用於包括分子生物學、蛋白質生產和疫苗研發在內的廣泛應用。

8. mRNA合成試劑盒包含多種組件，以滿足客戶的特定需求。特別是T7聚合酶，已成為最受歡迎的酵素類型，超過95%的mRNA合成試劑盒都包含此酵素。

9. 目前市面上約有115種mRNA合成試劑盒。這些試劑盒適用於多種應用，包括分子生物學、蛋白質生產和疫苗研發。

10. mRNA合成試劑盒包含多種組分，以滿足客戶的特定需求。特別是T7聚合酶，已成為最受歡迎的酵素類型，超過95%的mRNA合成試劑盒都包含此酵素。

11. 近年來，各利害關係人之間建立了多種合作關係，也反映了市場對該領域日益增長的興趣。事實上，約50%的交易是在過去三年內達成的。

12.全球眾多以mRNA為基礎的治療藥物和疫苗研發企業預計將與mRNA合成和生產服務提供者建立策略合作夥伴關係，以進一步拓展其藥物產品組合。

13. 賽諾菲在該領域佔主導地位，引領著大多數大型製藥公司在該領域的活動（約佔30%），其大部分舉措（50%）都是與該領域各利益相關方建立的合作夥伴關係和合作項目。

14. 北美目前佔mRNA合成和生產市場的大部分佔有率。這很可能是由於該地區擁有先進的醫療基礎設施，使企業能夠進行廣泛的研究。

15. 由於mRNA療法和疫苗在治療傳染病方面具有顯著療效，預計今年傳染病區隔市場將佔整體市場的大部分佔有率。

16. 預計北美將佔 mRNA 合成與製造市場的大部分佔有率，且這一趨勢預計將保持不變。

17. 受美國主要公司基於 mRNA 的疫苗和療法快速成功的推動，mRNA 合成與製造市場預計將以 6.5% 的複合年增長率增長。

mRNA合成與生產市場：主要區隔市場

mRNA 合成與生產市場的主要參與者

目錄

第一章：背景

第二章：研究方法

第三章：市場動態

第四章：宏觀經濟指標

第五章：摘要整理

第六章：引言

第七章：mRNA客製合成服務提供者：市場概況

第八章：競爭分析：mRNA客製合成服務提供者

第九章：mRNA合約生產服務提供者：市場概況

第十章：公司競爭分析：mRNA合約生產服務供應商供應商

第11章：mRNA合成試劑盒：市場概況

第12章：產品競爭分析：mRNA合成試劑盒

第13章：公司簡介：mRNA客製合成服務提供者

第十四章公司簡介：mRNA合約製造服務提供者

第十五章 公司簡介：mRNA 合成試劑盒

第十六章 合作與夥伴關係

第十七章 潛在夥伴分析

第18章：主要公司措施

第19章：市場影響分析

第20章：全球mRNA合成與生產市場

第20章

第21章：mRNA合成與生產市場（依產品類型劃分）

第22章：mRNA合成與生產市場（依企業規模劃分）

第23章：mRNA合成與生產市場（依合成與生產活動劃分）

第24章：mRNA合成與生產市場（依適應症類型劃分）

第25章：mRNA合成與生產市場（依治療領域劃分）

第26章：mRNA合成與生產市場（依應用劃分）

第27章：mRNA合成與生產市場（依地區劃分）

第28章：市場機會分析：北美

第29章：市場機會分析：歐洲

第30章：市場機會分析：亞太地區

第31章：市場機會分析：拉丁美洲

第32章：市場機會分析：中東與北非

第33章：結論

第34章：高階主管洞察

第35章：附錄一：表格資料

第36章：附錄二：公司與組織清單

MRNA SYNTHESIS AND MANUFACTURING MARKET: OVERVIEW

MRNA SYNTHESIS AND MANUFACTURING MARKET: GROWTH AND TRENDS